Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.54
+0.0000
Post-market: 3.540.00000.00%19:56 EDT
Volume:7.55M
Turnover:26.50M
Market Cap:1.16B
PE:-2.76
High:3.58
Open:3.48
Low:3.42
Close:3.54
Loading ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance

Simply Wall St.
·
05 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.17% as Chardan Cuts Price Target on Mixed Q4 Results

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan

TipRanks
·
04 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.08% After Analysts Cut Price Targets

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $15 from $25 at Truist

TIPRANKS
·
03 Mar

Stock Track | Iovance Biotherapeutics Soars 5.31% as Analysts Reaffirm "Buy" Ratings

Stock Track
·
03 Mar

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating

MT Newswires Live
·
03 Mar

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
01 Mar

Iovance Shares Fall After Sales of Cancer Drug Miss Estimate

Dow Jones
·
01 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Reports Surge in Q4 Revenue to US$74M with Improved Losses

Simply Wall St.
·
01 Mar

Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating

MT Newswires Live
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges Nearly 28% as Disappointing Earnings and Guidance Spook Investors

Stock Track
·
28 Feb

Stock Track | Iovance Biotherapeutics Plummets 27.66% on Disappointing Q4 Results and Cash Burn Outlook

Stock Track
·
28 Feb

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty

Zacks
·
28 Feb